现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2014年
8期
1905-1907
,共3页
伊立替康%替吉奥%晚期胃癌
伊立替康%替吉奧%晚期胃癌
이립체강%체길오%만기위암
irinotecan%S - 1%advanced gastric cancer
目的:观察伊立替康联合替吉奥二线治疗晚期胃癌的近期疗效和毒副反应。方法:27例晚期胃癌患者采用伊立替康270mg/ m2,静脉滴注,第1天;替吉奥60mg/ m2,分早、晚两次口服,第1-14天,21天为一个周期。结果:26例可评价疗效,其中 CR 1例,PR 8例,SD 8例,有效率34.6%,疾病控制率65.4%。常见毒副反应主要有恶心、呕吐、乏力、骨髓抑制、腹泻等,但多为 I/ II 度。结论:伊立替康联合替吉奥二线治疗晚期胃癌近期疗效较好,毒副反应可耐受。
目的:觀察伊立替康聯閤替吉奧二線治療晚期胃癌的近期療效和毒副反應。方法:27例晚期胃癌患者採用伊立替康270mg/ m2,靜脈滴註,第1天;替吉奧60mg/ m2,分早、晚兩次口服,第1-14天,21天為一箇週期。結果:26例可評價療效,其中 CR 1例,PR 8例,SD 8例,有效率34.6%,疾病控製率65.4%。常見毒副反應主要有噁心、嘔吐、乏力、骨髓抑製、腹瀉等,但多為 I/ II 度。結論:伊立替康聯閤替吉奧二線治療晚期胃癌近期療效較好,毒副反應可耐受。
목적:관찰이립체강연합체길오이선치료만기위암적근기료효화독부반응。방법:27례만기위암환자채용이립체강270mg/ m2,정맥적주,제1천;체길오60mg/ m2,분조、만량차구복,제1-14천,21천위일개주기。결과:26례가평개료효,기중 CR 1례,PR 8례,SD 8례,유효솔34.6%,질병공제솔65.4%。상견독부반응주요유악심、구토、핍력、골수억제、복사등,단다위 I/ II 도。결론:이립체강연합체길오이선치료만기위암근기료효교호,독부반응가내수。
To observe the short - term effects and adverse reactions of irinotecan combined with S - 1 as secongd - line treatment for advanced gastric cancer. Methods:Irinotecan was administered iv(270mg/ m2 )on day 1,while S - 1 was administered orally[60mg/(m2 ·day),bid]for 14 days followed by a 7 - day rest. This schedule was repeated every 3 weeks. Results:All 26 patients were evaluable,1 patient reached complete response(CR),8 partial responses(PR),8 stable disease. The overall response rate was 34. 6% ,disease control rate was 65. 4% . The major adverse effects were nausea and vomiting,fatigue,hematological,diarrhea. Conclusion:Irinotecan combined with S - 1 shows good efficacy as second - line in treatment for advanced gastric cancer. The quality of life can be im-proved and the toxicity is tolerable.